Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0008565,
umls-concept:C0032105,
umls-concept:C0086418,
umls-concept:C0144576,
umls-concept:C0184661,
umls-concept:C0205554,
umls-concept:C0370003,
umls-concept:C0392762,
umls-concept:C0599748,
umls-concept:C0678133,
umls-concept:C0680730,
umls-concept:C1148554,
umls-concept:C1521827,
umls-concept:C1720880,
umls-concept:C2347026
|
pubmed:issue |
5
|
pubmed:dateCreated |
1998-4-23
|
pubmed:abstractText |
A sensitive, specific, accurate and reproducible analytical method was developed and validated for the quantitation of the anticancer agent paclitaxel in human plasma. This procedure is based on high performance liquid chromatography/ion spray-tandem mass spectrometry. This methodology is highly specific because a MS/MS technique (multiple reactant-ion monitoring, MRM) was used for both paclitaxel and its internal standard. The use of a fully automated solid phase extraction procedure, using a CN Sep-pak cartridge, to improve the detection limit and quantification limit of paclitaxel in human plasma samples, was evaluated. The method involves the addition of methyl-paclitaxel as internal standard (i.s.). The retention times of paclitaxel and the I.S. were 2.8 and 4.0 min., respectively. The assay was linear over the range 5 to 500 ng/mL, with a quantification limit of 5 ng/mL having a coefficient of variation (c.v.) < 10%. Standard calibration curves, performed on three different days, had correlation coefficients always greater than 0.998. The intra and inter-day precision were within 12%, and accuracy was included in the range 102-110%. Paclitaxel recovery assessed at 15,250 and 500 ng/mL, was determined to be greater than 85%. The assay is applicable to clinical pharmacokinetic studies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0951-4198
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
251-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9519477-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:9519477-Chromatography, High Pressure Liquid,
pubmed-meshheading:9519477-Humans,
pubmed-meshheading:9519477-Indicators and Reagents,
pubmed-meshheading:9519477-Mass Spectrometry,
pubmed-meshheading:9519477-Paclitaxel,
pubmed-meshheading:9519477-Quality Control
|
pubmed:year |
1998
|
pubmed:articleTitle |
High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol) in human plasma.
|
pubmed:affiliation |
Laboratory of Environmental Hygiene and Industrial Toxicology, S. Maugeri Foundation, Pavia, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|